摘要
目的探讨醋酸甲地孕酮联合他莫昔芬治疗子宫内膜癌的疗效及其对血清TSGF、PRL、HE4的影响。方法选择大连大学附属中山医院2018年3月至12月收治的105例子宫内膜癌患者,随机分成2组。对照组50例,给予口服醋酸甲地孕酮片治疗;观察组55例,给予口服醋酸甲地孕酮片联合枸橼酸他莫昔芬片,治疗12周后,观察两组近期治疗效果及不良反应发生的情况,并采用酶联免疫吸附试验(ELISA法)分别检测两组患者治疗前后血清中TSGF、PRL、HE4表达水平。结果治疗12周后,对照组有效率为42.00%,临床获益率为68.00%;观察组有效率为65.45%,临床获益率为85.45%;两组治疗的有效率及临床获益率的差异均有统计学意义(P<0.05);两组患者血清TSGF、PRL、HE4表达水平均较治疗前明显降低,差异有统计学意义(P<0.01),两组间比较发现,观察组患者血清TSGF、PRL、HE4表达水平明显低于对照组,两组差异均有统计学意义(P<0.05);观察组不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论醋酸甲地孕酮与他莫昔芬联合治疗有助于提高子宫内膜癌临床治疗效果,降低患者血清TSGF、PRL、HE4表达水平,其发挥临床疗效可能与血清TSGF、PRL、HE4的表达有关。
Objective To investigate the clinical efficacy of medroxyprogesterone acetate combined with tamoxifen in the treatment of endometrial cancer and its effect on serum levels of TSGF,PRL and HE4.Methods 105 patients with endometrial cancer admitted to the hospital from March to December 2018 were randomly divided into 2 groups.50 cases in the control group were treated with medroxyprogesterone acetate tablets,55 cases in the observation group were treated with medroxyprogesterone acetate tablets combined with tamoxifen citrate tablets.After 12 weeks of treatment,the recent treatment effect and adverse reactions of the two groups were observed,and the expression levels of TSGF,PRL and HE4 in the serum of the two groups before and after treatment were detected by enzyme-linked immunosorbent assay(ELISA).Results After 12 weeks of treatment,the effective rate of the control group was 42.00%,the clinical benefit rate was 68.00%;the effective rate of the observation group was 65.45%,the clinical benefit rate was 85.45%;the difference of the effective rate and the clinical benefit rate between the two groups was statistically significant(P The results showed that the expression of TSGF,PRL and HE4 in the serum of the patients in the observation group was significantly lower than that in the control group(P<0.05);the incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusions Medroxyprogesterone acetate combined with tamoxifen can improve the clinical therapeutic effect of endometrial cancer and reduce the expression level of serum TSGF,PRL and HE4.Its clinical effect may be related to the expression of serum TSGF,PRL and HE4.
作者
高天明
付强
丛丽莉
崔晨丽
柳青
GAO Tianming;FU Qiang;CONG Lili;CUI Chenli;LIU Qing(Department of Obstetrics and Gynecology,Zhongshan Hospital Affiliated to Dalian University,Dalian 116001,China;Pharmacy of Shanxi General Hospital of PAP,Taiyuan 030006,China)
出处
《武警医学》
CAS
2020年第4期313-316,共4页
Medical Journal of the Chinese People's Armed Police Force
关键词
子宫内膜癌
醋酸甲地孕酮
他莫昔芬
人附睾分泌蛋白
endometrial cancer
medroxyprogesterone acetate
tamoxifen
human epididymis secreted protein
作者简介
高天明,硕士研究生,主任医师;通讯作者:柳青,E-mail:liuqingyjk@163.com
